Indaptus Therapeutics Raises $6 Million, Appoints David E. Lazar as Co-CEO and Chairman of the Board
ByAinvest
Monday, Dec 29, 2025 7:02 am ET1min read
INDP--
Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, who has been appointed Co-CEO and Chairman of the Board. The deal includes the purchase of non-voting convertible preferred stock and the appointment of Avraham Ben-Tzvi to the Board. The Company's lead product candidate and strategic opportunities will be evaluated, and the Board expects to hold a meeting in Q1 2026 to approve the conversion of the preferred stock.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet